Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Clinical trial NCT01511289 · COMPLETED

Trial details

NCT number: NCT01511289
Sponsor: Il-Yang Pharm. Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Philadelphia Chromosome Bone Marrow Diseases Hematologic Diseases

Start date: 2011-08-01
Primary completion: 2015-02-01
Enrollment: 242

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.